Interferon
drugOn this page
Summary
Interferon (CHEMBL2108494) is a phase-3 clinical-stage protein (ATC S01AD05) targeting IFNAR1; indicated across 17 conditions including eye infectious disorder and lymphoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- ATC class: S01AD05
- Targets: 1 (IFNAR1)
- Indications: 17 conditions
- Clinical trials: 144
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108494 |
| Name | Interferon |
| Type | Protein |
| Max phase | 3 |
| ATC | S01AD05 |
Also known as: Interferon, INTERFERON
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| IFNAR1 | interferon α/β receptor 1 | Agonist | 7.8 | 0.1% | P17181 |
| Interferon-α/β receptor | Agonist |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): IFNAR1.
Top Reactome pathways
16 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Cytokine Signaling in Immune system | 1 | IFNAR1 |
| Disease | 1 | IFNAR1 |
| Immune System | 1 | IFNAR1 |
| Infectious disease | 1 | IFNAR1 |
| Interferon alpha/beta signaling | 1 | IFNAR1 |
| Regulation of IFNA/IFNB signaling | 1 | IFNAR1 |
| Interferon Signaling | 1 | IFNAR1 |
| Potential therapeutics for SARS | 1 | IFNAR1 |
| SARS-CoV Infections | 1 | IFNAR1 |
| SARS-CoV-2 Infection | 1 | IFNAR1 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | 1 | IFNAR1 |
| SARS-CoV-2-host interactions | 1 | IFNAR1 |
| Respiratory Syncytial Virus Infection Pathway | 1 | IFNAR1 |
| Viral Infection Pathways | 1 | IFNAR1 |
| Evasion by RSV of host interferon responses | 1 | IFNAR1 |
| RSV-host interactions | 1 | IFNAR1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| cell surface receptor signaling pathway via JAK-STAT | 1 |
| response to virus | 1 |
| response to lipopolysaccharide | 1 |
| cellular response to interferon-alpha | 1 |
| cellular response to interferon-beta | 1 |
| type I interferon-mediated signaling pathway | 1 |
| cellular response to virus | 1 |
| positive regulation of cellular respiration | 1 |
| regulation of transcription by RNA polymerase II | 1 |
| positive regulation of metabolic process | 1 |
| cytokine-mediated signaling pathway | 1 |
| regulation of receptor signaling pathway via JAK-STAT | 1 |
| positive regulation of protein localization to nucleus | 1 |
Indications & clinical
Indications
17 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| eye infectious disorder | 4 | MONDO:0043885 | EFO:1001888 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| colonic neoplasm | 3 | MONDO:0005401 | MONDO:0021063 |
| renal cell carcinoma | 2 | MONDO:0005086 | EFO:0000681 |
| chronic hepatitis C virus infection | 2 | MONDO:0005354 | EFO:0004220 |
| melanoma | 2 | MONDO:0005105 | EFO:0000756 |
| Zollinger-Ellison syndrome | 2 | MONDO:0019610 | EFO:0007549 |
| pancreatic neuroendocrine neoplasm | 2 | MONDO:0005815 | EFO:0007331 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
| interstitial cystitis | 2 | MONDO:0018301 | EFO:0008507 |
| neoplasm | 2 | MONDO:0005070 | MONDO:0004992 |
| hepatitis C virus infection | 1 | MONDO:0005231 | EFO:0003047 |
| cirrhosis of liver | 1 | MONDO:0005155 | EFO:0001422 |
| influenza | 1 | MONDO:0005812 | EFO:0007328 |
| liver disorder | 1 | MONDO:0005154 | EFO:0001421 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 144.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 43 |
| PHASE2 | 36 |
| PHASE3 | 29 |
| PHASE1 | 13 |
| PHASE4 | 9 |
| PHASE1/PHASE2 | 9 |
| PHASE2/PHASE3 | 4 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06503796 | PHASE4 | NOT_YET_RECRUITING | Antiviral Therapy in Infants With HBV Infection |
| NCT00132210 | PHASE4 | COMPLETED | Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients |
| NCT00167557 | PHASE4 | WITHDRAWN | Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment |
| NCT00194480 | PHASE4 | COMPLETED | Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users |
| NCT00266318 | PHASE4 | COMPLETED | Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy |
| NCT00390897 | PHASE4 | COMPLETED | Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia |
| NCT00560690 | PHASE4 | COMPLETED | The Effect of Adding Metformin to the Treatment of Hepatitis C |
| NCT00780455 | PHASE4 | TERMINATED | Rehabilitation Study in MS Patients |
| NCT03357822 | PHASE4 | UNKNOWN | A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B |
| NCT06802718 | PHASE3 | RECRUITING | Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia |
| NCT00075998 | PHASE3 | TERMINATED | The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) |
| NCT00099502 | PHASE3 | COMPLETED | BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients |
| NCT00140569 | PHASE3 | COMPLETED | Randomized Study for Patients With Follicular Lymphoma Needing Treatment |
| NCT00147784 | PHASE3 | COMPLETED | HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group. |
| NCT00185211 | PHASE3 | COMPLETED | BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study |
| NCT00209209 | PHASE3 | UNKNOWN | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL |
| NCT00270816 | PHASE2/PHASE3 | COMPLETED | Interferon ß-1b Treatment by Cyclical Administration |
| NCT00273247 | PHASE3 | COMPLETED | Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis |
| NCT00309530 | PHASE3 | COMPLETED | Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C |
| NCT00311467 | PHASE3 | TERMINATED | Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma |
| NCT00313976 | PHASE3 | WITHDRAWN | Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) |
| NCT00340834 | PHASE3 | COMPLETED | Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase |
| NCT00370071 | PHASE3 | COMPLETED | Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis |
| NCT00459667 | PHASE3 | COMPLETED | BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose |
| NCT00538811 | PHASE2/PHASE3 | COMPLETED | Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders |
| NCT00577993 | PHASE3 | COMPLETED | Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients |
| NCT00633542 | PHASE3 | COMPLETED | Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) |
| NCT00883337 | PHASE3 | COMPLETED | A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis |
| NCT01064401 | PHASE3 | COMPLETED | Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis |
| NCT01247324 | PHASE3 | COMPLETED | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis |
| NCT01412333 | PHASE3 | COMPLETED | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis |
| NCT01463592 | PHASE3 | UNKNOWN | To Study the Efficacy and Safety of Renessans in Chronic HCV Patients |
| NCT01858961 | PHASE3 | WITHDRAWN | Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients |
| NCT01860742 | PHASE3 | WITHDRAWN | Randomized Phase III of PRRT Versus Interferon |
| NCT02047734 | PHASE3 | COMPLETED | Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis |
| NCT02283853 | PHASE3 | COMPLETED | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) |
| NCT02415127 | PHASE3 | COMPLETED | Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich’s Ataxia |
| NCT02593773 | PHASE3 | COMPLETED | Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich’s Ataxia Study |
| NCT02797080 | PHASE3 | COMPLETED | Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich’s Ataxia |
| NCT04356495 | PHASE2/PHASE3 | COMPLETED | Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Genes: IFNAR1
- Diseases: eye infectious disorder, lymphoma, colonic neoplasm